Pargyline reduces/prevents neuroleptic-induced acute dystonia in monkeys

R. Heintz, Daniel Casey

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The neuropharmacologic mechanisms underlying neuroleptic-induced extrapyramidal syndromes (EPS) were studied using a nonhuman primate model. Twenty-six Cebus albifrons monkeys were given weekly challenges of haloperidol (0.025 mg/kg IM), and half of the animals received the monoamine oxidase (MAO) inhibitor pargyline (5 mg/kg PO) daily for 17 consecutive days during the protocol. Pargyline caused no changes in baseline behaviors, but significantly reduced haloperidol-induced acute dystonia (AD) (-67%, P

Original languageEnglish (US)
Pages (from-to)207-213
Number of pages7
JournalPsychopharmacology
Volume93
Issue number2
DOIs
StatePublished - Oct 1987

Fingerprint

Pargyline
Dystonia
Antipsychotic Agents
Haplorhini
Cebus
Monoamine Oxidase Inhibitors
Haloperidol
Primates
4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol

Keywords

  • Cebus albifrons monkeys
  • Dystonia
  • Extrapyramidal syndromes
  • Monoamine oxidase
  • Neuroleptics
  • Pargyline
  • Primates

ASJC Scopus subject areas

  • Pharmacology

Cite this

Pargyline reduces/prevents neuroleptic-induced acute dystonia in monkeys. / Heintz, R.; Casey, Daniel.

In: Psychopharmacology, Vol. 93, No. 2, 10.1987, p. 207-213.

Research output: Contribution to journalArticle

Heintz, R. ; Casey, Daniel. / Pargyline reduces/prevents neuroleptic-induced acute dystonia in monkeys. In: Psychopharmacology. 1987 ; Vol. 93, No. 2. pp. 207-213.
@article{3f726589b05e48389a03c5b05336772e,
title = "Pargyline reduces/prevents neuroleptic-induced acute dystonia in monkeys",
abstract = "The neuropharmacologic mechanisms underlying neuroleptic-induced extrapyramidal syndromes (EPS) were studied using a nonhuman primate model. Twenty-six Cebus albifrons monkeys were given weekly challenges of haloperidol (0.025 mg/kg IM), and half of the animals received the monoamine oxidase (MAO) inhibitor pargyline (5 mg/kg PO) daily for 17 consecutive days during the protocol. Pargyline caused no changes in baseline behaviors, but significantly reduced haloperidol-induced acute dystonia (AD) (-67{\%}, P",
keywords = "Cebus albifrons monkeys, Dystonia, Extrapyramidal syndromes, Monoamine oxidase, Neuroleptics, Pargyline, Primates",
author = "R. Heintz and Daniel Casey",
year = "1987",
month = "10",
doi = "10.1007/BF00179935",
language = "English (US)",
volume = "93",
pages = "207--213",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Pargyline reduces/prevents neuroleptic-induced acute dystonia in monkeys

AU - Heintz, R.

AU - Casey, Daniel

PY - 1987/10

Y1 - 1987/10

N2 - The neuropharmacologic mechanisms underlying neuroleptic-induced extrapyramidal syndromes (EPS) were studied using a nonhuman primate model. Twenty-six Cebus albifrons monkeys were given weekly challenges of haloperidol (0.025 mg/kg IM), and half of the animals received the monoamine oxidase (MAO) inhibitor pargyline (5 mg/kg PO) daily for 17 consecutive days during the protocol. Pargyline caused no changes in baseline behaviors, but significantly reduced haloperidol-induced acute dystonia (AD) (-67%, P

AB - The neuropharmacologic mechanisms underlying neuroleptic-induced extrapyramidal syndromes (EPS) were studied using a nonhuman primate model. Twenty-six Cebus albifrons monkeys were given weekly challenges of haloperidol (0.025 mg/kg IM), and half of the animals received the monoamine oxidase (MAO) inhibitor pargyline (5 mg/kg PO) daily for 17 consecutive days during the protocol. Pargyline caused no changes in baseline behaviors, but significantly reduced haloperidol-induced acute dystonia (AD) (-67%, P

KW - Cebus albifrons monkeys

KW - Dystonia

KW - Extrapyramidal syndromes

KW - Monoamine oxidase

KW - Neuroleptics

KW - Pargyline

KW - Primates

UR - http://www.scopus.com/inward/record.url?scp=0023547662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023547662&partnerID=8YFLogxK

U2 - 10.1007/BF00179935

DO - 10.1007/BF00179935

M3 - Article

C2 - 2827216

AN - SCOPUS:0023547662

VL - 93

SP - 207

EP - 213

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 2

ER -